Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer-Reference-Cited by-同舟云学术

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Published:2011-01-28 Issue:6 Volume:17 Page:1591-1602
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Konecny Gottfried E.,Winterhoff Boris,Kolarova Teodora,Qi Jingwei,Manivong Kanthinh,Dering Judy,Yang Guorong,Chalukya Meenal,Wang He-Jing,Anderson Lee,Kalli Kimberly R.,Finn Richard S.,Ginther Charles,Jones Siân,Velculescu Victor E.,Riehle Darren,Cliby William A.,Randolph Sophia,Koehler Maria,Hartmann Lynn C.,Slamon Dennis J.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor–induced arrest;Proceedings of the National Academy of Sciences;2024-07-18

2. Cell cycle machinery in oncology: A comprehensive review of therapeutic targets;The FASEB Journal;2024-06-07

3. Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?;Cancers;2024-05-13

4. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

5. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo;Molecular Biology Reports;2024-03-27